JPMorgan upgraded H.B. Fuller to Neutral from Underweight with an unchanged price target of $58. The firm says the near-term share price performance may be determined by whether Fuller proceeds with the Advanced Medical Solutions transaction or initiates a full review of strategic alternatives. It cites valuation for the upgrade.
